- Home
- APRE
as 04-23-2025 4:00pm EST
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DOYLESTOWN |
| Market Cap: | 13.5M | IPO Year: | 2019 |
| Target Price: | $15.50 | AVG Volume (30 days): | 29.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.41 - $5.90 | Next Earning Date: | 05-13-2025 |
| Revenue: | $1,502,581 | Revenue Growth: | 157.63% |
| Revenue Growth (this year): | -38.91% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Aprea Therapeutics Inc. Common stock (APRE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gilad Oren | APRE | President/CEO | Apr 3 '25 | Buy | $1.84 | 5,500 | $10,110.21 | 343,123 |
Latest Aprea Therapeutics Inc. Common stock News
APRE Breaking Stock News: Dive into APRE Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
23 days ago
Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial
GlobeNewswire
24 days ago
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
Simply Wall St.
a month ago
Aprea Therapeutics Full Year 2024 Earnings: Beats Expectations
GlobeNewswire
a month ago
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
GlobeNewswire
a month ago
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
TipRanks
3 months ago
Aprea Therapeutics provides update on existing patent portfolio
GlobeNewswire
3 months ago
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
GlobeNewswire
4 months ago
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
Compare APRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APRE Aprea Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.